Clinical experience with non-nucleoside reverse transcreptase inhibitors: L-697,661 and nevirapine

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 291-298

  Kilby, J Michael ^a   Saag, Michael S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; ANTIVIRUS AGENT; L 345516; L 693593; L 696040; L 697693; L 735525; NEVIRAPINE; RITONAVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; VIROGENESIS; VIRUS TRANSMISSION;

BENZOXAZOLES; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; NEVIRAPINE; PYRIDINES; PYRIDONES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029877695     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_26     Document Type: Article

References (23)

1. Hirsch MS, D'Aquila RT. Therapy for HIV Infection. N Engl J Med 1993;328: 1686-95.
2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-191.
3. Richman DD. Viral resistance to antiretroviral therapy. In: Broder S, Merigan TC, Bolognesi D, eds. Textbook of AIDS medicine. Baltimore: Williams and Wilkins, 1994:795-80.
4. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994;343:871-81.
5. Saag MS. Nucleoside analogues: adverse effects. Hosp Prac 1992;27(suppl 2):26-36.
6. Miyasaka T, Tanaka H, Baba M, et al. A novel lead for specific anti-HIV-1 agents: 1-[2-hydroxyethoxymethyl]-6-(phenylthio)thymine. J Med Chem 1989;32:2507 .
7. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives Nature. 1990;343:470-4.
8. Pauwels R, Andries K, Debyser Z, et al. Potent and highly selective HIV-1 inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 RT. Proc Natl Acad Sci USA 1993;90:1711-15.
9. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a non-nucleoside RT inhibitor. Science 1990;250:1411-13.
10. Goldman ME, Nunberg JH, O'Brien JA, et al. Pyridinone derivatives: specific HIV-1 RT inhibitors with antiviral activity. Proc Natl Acad Sci USA 1991;88:6863-7.
11. Romero DL, Busso M, Tan C-K, et al. Nonnucleoside RT inhibitors that potently and specifically block HIV-1 replication. Proc Natl Acad Sci USA 1991;88:8806-10.
12. De Clercq E. HIV-1 specific inhibitors: highly selective inhibitors of HIV-1 that are specifically targeted at the reverse transcriptase. Med Res Rev 1993;13:229-58.
13. Nunberg JH, Schleif WA, Boots EJ, et al. Viral resistance to HIV-1-specific pyridinone inhibitors. J Virol 1991;65:4887-92.
14. Saag MS, Emini EA, Laskin OL, et al. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993;329:1065-72.
15. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 angstrom resolution of HIV-1 RT complexed to an inhibitor. Science 1992;256:1783-90.
16. Shin C-K, Rose IM, Hansen JL, et al. Chimceric HIV type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci USA 1991;88: 9878-82.
17. Richman DD, Shih C-K, Lowy, et al. HIV-1 mutants resistant to nonnucleoside inhibitors of RT arise in tissue culture. Proc Natl Acad Sci USA 1991;88: 11241-5.
18. Cheeseman SH. Nevirapine alone and in combination with AZT: safety and activity[Abstract MoB0053]. Presented at the combined VIII International Conference on AIDS/HIV and the STD World Congress, Amsterdam, The Netherlands, 1992.
19. Saag M, Johnson V, Wei X, et al. Clinical, pharmacokinetic, and virologic results in adults treated with nevirapine in combination with AZT/ddC, AZT/ddI, or ddI alone final report of the BI1009 study. [Abstract M16]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.
20. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
21. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
22. Kilby JM, Taylor M, Wei X, et al. In situ expression and functional analysis of HIV-1 reverse transcriptase (RT) in patients treated with nevirapine, AZT, and ddI. (Abstract 1216]. Presented al the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994.
23. Kilby JM, Saag MS. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection? Infectious Agents and Disease, 1994;3:313-323.